RPS6KB1 and B-cell chronic lymphocytic leukemia: The CLL-microvesicles can activate the AKT target of rapamycin/p70S6K/hypoxia-inducible factor-1α axis in CLL bone marrow stromal cells (BMSCs) with production of vascular endothelial growth factor, a survival factor for CLL B-cells.